WBI Investments LLC Has $1.26 Million Position in McKesson Corporation $MCK

WBI Investments LLC lessened its stake in McKesson Corporation (NYSE:MCK) by 26.3% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 1,627 shares of the company’s stock after selling 582 shares during the period. WBI Investments LLC’s holdings in McKesson were worth $1,257,000 as of its most recent filing with the SEC.

A number of other institutional investors have also added to or reduced their stakes in the company. Norges Bank acquired a new position in McKesson in the 2nd quarter valued at approximately $1,346,661,000. Alliancebernstein L.P. lifted its position in shares of McKesson by 150.4% in the 2nd quarter. Alliancebernstein L.P. now owns 2,268,015 shares of the company’s stock worth $1,661,956,000 after acquiring an additional 1,362,386 shares during the period. Arrowstreet Capital Limited Partnership grew its holdings in shares of McKesson by 56.4% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 1,236,536 shares of the company’s stock worth $906,109,000 after purchasing an additional 446,060 shares in the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main increased its position in shares of McKesson by 45.6% during the second quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 833,780 shares of the company’s stock valued at $610,977,000 after purchasing an additional 261,296 shares during the period. Finally, Vanguard Group Inc. increased its position in shares of McKesson by 2.0% during the second quarter. Vanguard Group Inc. now owns 12,072,090 shares of the company’s stock valued at $8,846,186,000 after purchasing an additional 232,286 shares during the period. 85.07% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the company. JPMorgan Chase & Co. raised their target price on McKesson from $983.00 to $1,107.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 10th. Zacks Research lowered shares of McKesson from a “strong-buy” rating to a “hold” rating in a report on Tuesday, November 25th. Leerink Partners restated an “outperform” rating and issued a $1,085.00 price objective on shares of McKesson in a research note on Thursday, March 5th. Evercore reaffirmed an “outperform” rating on shares of McKesson in a report on Thursday, March 5th. Finally, Wells Fargo & Company lifted their target price on shares of McKesson from $914.00 to $925.00 and gave the company an “equal weight” rating in a research report on Thursday, February 5th. Thirteen investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $960.93.

Insider Buying and Selling at McKesson

In other McKesson news, CAO Napoleon B. Rutledge, Jr. sold 328 shares of the company’s stock in a transaction dated Friday, February 6th. The shares were sold at an average price of $955.00, for a total transaction of $313,240.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Maria Martinez sold 349 shares of the firm’s stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $939.87, for a total transaction of $328,014.63. Following the sale, the director directly owned 301 shares of the company’s stock, valued at approximately $282,900.87. The trade was a 53.69% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 3,868 shares of company stock worth $3,743,820 over the last ninety days. Company insiders own 0.08% of the company’s stock.

McKesson Price Performance

McKesson stock opened at $942.57 on Wednesday. The business has a 50 day simple moving average of $898.61 and a 200 day simple moving average of $830.00. The company has a market capitalization of $115.45 billion, a PE ratio of 27.11, a price-to-earnings-growth ratio of 1.52 and a beta of 0.38. McKesson Corporation has a one year low of $637.00 and a one year high of $999.00.

McKesson (NYSE:MCK) last announced its quarterly earnings results on Wednesday, February 4th. The company reported $9.34 earnings per share for the quarter, beating analysts’ consensus estimates of $9.19 by $0.15. The firm had revenue of $106.16 billion for the quarter, compared to analysts’ expectations of $105.98 billion. McKesson had a negative return on equity of 338.97% and a net margin of 1.09%.The business’s revenue was up 11.4% compared to the same quarter last year. During the same period in the prior year, the business posted $8.03 earnings per share. McKesson has set its FY 2026 guidance at 38.800-39.200 EPS. Equities analysts anticipate that McKesson Corporation will post 32.77 earnings per share for the current fiscal year.

McKesson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, April 1st. Investors of record on Monday, March 2nd will be given a dividend of $0.82 per share. The ex-dividend date is Monday, March 2nd. This represents a $3.28 dividend on an annualized basis and a dividend yield of 0.3%. McKesson’s dividend payout ratio (DPR) is 9.43%.

McKesson Profile

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.